XML 45 R25.htm IDEA: XBRL DOCUMENT v3.25.1
STATEMENTS OF PROFIT OR LOSS - ADDITIONAL INFORMATION
 12 Months Ended
Dec. 31, 2024
Disclosure Of Statements Of Comprehensive Loss Additional Information [Abstract]  
STATEMENTS OF PROFIT OR LOSS – ADDITIONAL INFORMATION
NOTE 19: - STATEMENTS OF PROFIT OR LOSS – ADDITIONAL INFORMATION
 
  a.
Cost of revenues:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Salaries and benefits
  
$
747
    
$
432
    
$
238
  
Materials and sub-contractors
    
1,936
      
1,260
      
671
  
                         
   
$
2,683
    
$
1,692
    
$
909
  

 

  b.
Research and development, net:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Salaries and benefits
  
$
8,509
    
$
9,862
    
$
11,545
  
Share-based compensation
    
360
      
764
      
593
  
Materials and sub-contractors
    
4,152
      
6,349
      
5,514
  
Plant growth and greenhouse maintenance
    
456
      
744
      
839
  
Office maintenance
    
651
      
639
      
437
  
Depreciation and amortization
    
2,440
      
2,549
      
2,540
  
Gain from derecognition of property, plant and equipment
    
-
      
(26
)
    
-
  

Amounts recorded with respect to government grants (*)

    
48
      
(143
)
    
(726
)
Other
    
32
      
39
      
50
  
                         
   
$
16,648
    
$
20,777
    
$
20,792
  
 
*) Excludes EU Horizon participation amounts, that were deducted from specific expense items above
 
  c.
Sales and marketing:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Salaries and benefits
  
$
1,979
    
$
1,996
    
$
2,475
  
Share-based compensation
    
603
      
595
      
323
  
Subcontractors and professional fees
    
564
      
855
      
883
  
Travel
    
245
      
142
      
76
  
Legal
    
21
      
10
      
120
  
Other
    
13
      
13
      
56
  
                         
   
$
3,425
    
$
3,611
    
$
3,933
  

 

  d.
General and administrative:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Salaries and benefits
  
$
2,914
    
$
2,902
    
$
2,929
  
Share-based compensation
    
757
      
518
      
270
  
Professional fees
    
3,436
      
2,281
      
2,876
  
Other
    
334
      
367
      
407
  
                         
   
$
7,441
    
$
6,068
    
$
6,482
 
  e.
Other expenses (income):
 
  1.
During the year ended December 31, 2022, the Company received an amount of $3,500 from Bayer Cropscience LP under their joint seed traits collaboration agreement with Evogene, as part of a restructuring and release of its patent filing, prosecution, and maintenance obligation under the collaboration. According to the agreement, the Company has no further filing, prosecution, and maintenance obligation with respect to the patent rights deriving from this collaboration.

 

  2.
The decision to cease Canonic Ltd.’s operations in the first half of 2024 resulted in other expenses of approximately $524, mainly due to impairment of fixed assets in the first quarter of 2024.
 
  f.
Financing income and expenses:
 
Financing income:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Exchange differences
  
$
13
    
$
167
    
$
319
  
Interest income
    
957
      
1,248
      
182
  
Financial income in respect of government grants
    
47
      
26
      
15
  
Change in the fair value of marketable Securities
    
-
      
45
      
-
  

Remeasurement of warrants and pre-funded warrants

    
6,529
      
-
      
-
  
                         
   
$
7,546
    
$
1,486
    
$
516
  

 

Financing expenses:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Bank expenses and commissions
  
$
61
    
$
56
    
$
76
  
Exchange differences
    
60
      
412
      
2,060
  
Change in the fair value of marketable securities
    
-
      
-
      
721
  
Excess of initial fair value of pre-funded warrants over transaction proceeds
    
2,684
      
-
      
-
  
Amortization of deferred expenses related to issuance of warrants
    
471
      
-
      
-
  
Lease liability interest
    
63
      
115
      
165
  
Revaluation of Convertible SAFE
    
3
      
254
      
114
  
Financial expenses in respect of government grants
    
-
      
128
      
193
  
                         
   
$
3,342
    
$
965
    
$
3,329